Hair loss associated with GLP-1 medications appears to be multifactorial rather than a direct drug effect
These included downregulation of myogenic regulatory genes such as Pax7 , Myf5 , and Cyclin D1 , as well as impairments in Notch signaling and oxidative phosphorylation pathways
By activating the GIP and GLP-1 receptors, tirzepatide increases insulin secretion, reduces glucagon release, slows down gastric emptying, and promotes a feeling of fullness or satiety
That tells us something important medications can amplify the results of behavior change, and behavior change boosts the chance those results last
doi:10.1001/jama.2021.21392
Abstract The current absence of effective treatments for Alzheimers disease (AD) and Parkinsons disease (PD) reflects an incomplete knowledge of the underlying disease processes